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RAS pathway mutations as a predictive biomarker for
treatment adaptation in pediatric B-cell precursor acute
lymphoblastic leukemia
IS Jerchel1, AQ Hoogkamer1, IM Ariës1, EMP Steeghs1, JM Boer1, NJM Besselink2,3, A Boeree1, C van de Ven1,
HA de Groot-Kruseman4, V de Haas4,5, MA Horstmann6,7, G Escherich6,7, CM Zwaan1, E Cuppen2,3, MJ Koudijs2,3, R Pieters4,5
and ML den Boer1,4
RAS pathway mutations have been linked to relapse and chemotherapy resistance in pediatric B-cell precursor acute lymphoblastic
leukemia (BCP-ALL). However, comprehensive data on the frequency and prognostic value of subclonal mutations in well-deﬁned
subgroups using highly sensitive and quantitative methods are lacking. Targeted deep sequencing of 13 RAS pathway genes was
performed in 461 pediatric BCP-ALL cases at initial diagnosis and in 19 diagnosis-relapse pairs. Mutations were present in 44.2% of
patients, with 24.1% carrying a clonal mutation. Mutation frequencies were highest in high hyperdiploid, infant t(4;11)-rearranged,
BCR-ABL1-like and B-other cases (50–70%), whereas mutations were less frequent in ETV6-RUNX1-rearranged, and rare in TCF3-PBX1-
and BCR-ABL1-rearranged cases (27–4%). RAS pathway-mutated cells were more resistant to prednisolone and vincristine ex vivo.
Clonal, but not subclonal, mutations were linked to unfavorable outcome in standard- and high-risk-treated patients. At relapse,
most RAS pathway mutations were clonal (9 of 10). RAS mutant cells were sensitive to the MEK inhibitor trametinib ex vivo, and
trametinib sensitized resistant cells to prednisolone. We conclude that RAS pathway mutations are frequent, and that clonal, but
not subclonal, mutations are associated with unfavorable risk parameters in newly diagnosed pediatric BCP-ALL. These mutations
may designate patients eligible for MEK inhibitor treatment.
Leukemia (2018) 32, 931–940; doi:10.1038/leu.2017.303
INTRODUCTION
The prognosis of children with B-cell precursor acute lympho-
blastic leukemia (BCP-ALL) has improved considerably over the
past decades, and nowadays about 80% of the patients are cured.1
However, especially medium- and high-risk cases still show
dissatisfying rates of relapse despite intense chemotherapy.2–4
Relapsed ALL is treated with the same drugs as the initial
leukemia, but cells of relapsed cases are more resistant.5 New,
targeted approaches are therefore warranted.
Activating mutations in KRAS, NRAS and HRAS are among the
most frequent mutations in cancer.6–9 The RAS GTPases are
convert extracellular growth signals into a complex intracellular
response. Upon activation of a growth factor receptor, RAS-
guanidine exchange factors (e.g. SHP2 encoded by PTPN11)
activate RAS by enabling binding of GTP, which activates the
RAF and PI3 kinases and RALGDS. The RAF–MEK–ERK kinase axis is
crucial for mediating the oncogenic effects of RAS, demonstrated
by the efﬁcacy of MEK inhibitors in RAS-mutated cancers.10–12
Clinical trials are ongoing, and beneﬁts were reported for RAF-
mutated melanomas, ovarian cancer and thyroid cancer.13–18
RAS mutations have been initially reported in about 15% of
pediatric BCP-ALL.19–21 However, these studies were often
restricted to N- and KRAS, certain subtypes or high-risk groups,
or were technically limited in sensitivity (therefore overlooking
subclonal mutations), and did not compare mutation frequencies
between cytogenetic subtypes.22–26 Mutations were reported in
the context of recent genomic studies but not studied for their
prognostic impact in isolation. Therefore, the clinical signiﬁcance
of RAS mutations is still debated, and it is unknown whether the
recent inclusion of minimal residual disease (MRD) levels as risk
criterion inﬂuences the prognostic effect of RAS pathway
mutations in contemporary protocols. Recent studies found that
mutations in NRAS, KRAS, FLT3 and PTPN11 are more frequently
observed at relapse (34–38%), and in part confer a poor
prognosis.26–29 We previously observed in a small cohort of 26
patients that RAS pathway mutations are more frequent in ex vivo
prednisolone-resistant cases, which are sensitized to prednisolone
by RAS pathway inhibition.30 Backtracking has shown that RAS-
mutant relapse-forming clones may exist as small subclones at
initial diagnosis.27,31,32 However, these retrospective analyses rely
on selected cases, and the predictive value of (sub)clonal RAS
pathway mutations at initial diagnosis of BCP-ALL treated in
contemporary protocols is unknown.
Here we report deep next-generation sequencing of 13 RAS
pathway genes together with a risk-stratiﬁed survival analysis in a
clinically and biologically well-characterized cohort of 461 initial
diagnosis patients with BCP-ALL, treated according to a con-
temporary, MRD-based ALL treatment protocol (DCOG ALL10). In
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addition, we report links between RAS mutation status, clonality,
ex vivo cellular drug resistance and ex vivo response to MEK
inhibition.
MATERIALS AND METHODS
A detailed description of all methods can be found in the online
Supplementary Data.
Patient material 2 and patient-derived xenografts
This study comprised children with newly diagnosed BCP-ALL with an age
range of 0–18 years. These studies were conducted in accordance with the
Declaration of Helsinki; written informed consent was obtained from
parents or guardians and approval given by institutional review boards.
Mononuclear cells were isolated using density gradient centrifugation with
Lymphoprep (Axis Shield, Oslo, Norway) as described previously.33 Animal
experiments were approved by the animal ethics committee (EMC 2863
(103-12-08)). In some cases, xenografts of primary patient material were
established in three 7–12-week-old female NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ
(NSG) mice per patient (Charles River, Leiden, Netherlands). Leukemic cells
were isolated and subsequently used for sequencing, western blot and
trametinib (GSK1120212) cytotoxicity assays. For all samples leukemic blast
percentage was at least 90%, and in relapse samples blast percentage was
at least 80%. Subtypes were determined by karyotype, ﬂuorescence in situ
hybridization and/or fusion-gene speciﬁc PCR. BCR-ABL1-like cases were
identiﬁed using microarray gene expression proﬁling by means of a 110
probe set classiﬁer.34,35 The composition of analyzed groups is described in
a ﬂow diagram (Supplementary Figure S1).
Ex vivo cytotoxicity assays
Sensitivity towards chemotherapeutics was evaluated as previously
described.36 In brief, freshly isolated primary ALL cells were incubated
with a concentration range of prednisolone, vincristine, daunorubicin,
L-asparaginase, 6-mercaptopurine and 6-thioguanine. After 4 days, cell
viability was evaluated by adding MTT and measuring formazan
conversion with optical density measurement. LC50 values were calculated
(concentration at which 50% conversion activity was measured relative to
no-drug control cells) and compared between groups using Mann–
Whitney U-tests. Ex vivo sensitivity towards trametinib was measured
similarly (5 μM–0.6 nM).
Sequencing and code availability
DNA and RNA were isolated using Trizol reagent (Life Technologies,
Bleiswijk, Netherlands), or using DNeasy (Qiagen, Hilden, Germany) in two
cases (used only for trametinib sensitivity assay) and the cell line 697. For
TruSeq Custom Amplicon sequencing (Illumina, San Diego, CA, USA),
sequencing libraries were prepared from 100 to 250 ng genomic DNA.
Successful library preparation was conﬁrmed using the Labchip GX
genomic analyzer (Caliper Life Sciences Benelux N.V., the Netherlands).
Samples were then pooled equimolarly and sequenced on an Illumina
MiSeq in paired-end reads of 250 bp each. Forty-nine amplicons of 425 bp
covered mutational hotspot regions in 13 RAS pathway genes
(Supplementary Table S1). The analysis script will be provided upon
request.
Sequence reads were aligned to the 1000 genomes human reference
sequences (version b37, GATK resource bundle; Broad Institute, Cambridge,
MA, USA) using BWA v0.7.1037 and GATK indel realigner v.3.3-0. Single-
nucleotide variants were called with Freebayes v0.9.18–24,38 Varscan v.2.3.
7,39 Bcftools v1.040 and GATK v3.3-0.41 The resulting variant call format ﬁles
were annotated using snpEff and snpSift v.4.1a42 and dbNSFP v.2.7.43 For
reliable detection of high-conﬁdence mutations, variants were ﬁltered
based on several criteria: For each sample, variants were excluded if they
were reported by only one caller, coverage was o100 reads, or o20
reads supported the variant allele. Overall, variants were excluded if variant
allele frequency (VAF) never exceeded 2% or distribution was unequal
between runs. Furthermore, variants were only considered if they were
reported in the COSMIC V73 GRCh37 database,44 non-synonymous,
unlikely to be germline variants and not known SNPs (see
Supplementary Methods for details). Read depth per amplicon is
summarized in Supplementary Table S1. An estimate of cases missed
due to insufﬁcient coverage is given in Supplementary Table S2. In a
comparison with 25 samples that were sequenced previously,30 all variants
could be identiﬁed by both platforms, indicating a low false-positive rate.
Only Exon 3 of NRAS was sequenced using Sanger sequencing in 248
ALL10 samples since primer design for this exon in a multiplex amplicon
setting failed. Chromatograms were visually inspected for the presence of
mutations in codons 59 to 63 as well as analyzed by the R package
sangerseqR in combination with the tools above to call and annotate
detected variants.
Clinical characteristics and statistics
Clinical characteristics were compared using Fisher’s exact test in R
(version 3.2.1). We analyzed cases from the Dutch Childhood Oncology
Group (DCOG) and Cooperative Study Group for Children with ALL (COALL)
(n=432). We restricted the RAS pathway-mutated group to those carrying
a veriﬁed MAPK pathway activating mutation (codons 12, 13 and 146 of
NRAS or KRAS and FLT3 or PTPN11). Event-free survival and cumulative
incidence of relapse and non-response after induction therapy were
evaluated in 244 eligible cases treated within one protocol (DCOG ALL10),
stratiﬁed for risk group. The COALL97/03 cohort consisted of patients
treated in the consecutive COALL 06–97 and COALL 07-03 protocols
(n=131). For details see Escherich et al.45 Treatment intensity in arms LR-R
and LR-S is comparable to DCOG ALL10 standard-risk treatment; LR-I, HR-R
and HR-S treatment is comparable to DCOG ALL10 medium-risk treatment.
In the COALL97/03 cohort, no patient was treated with an intensity
comparable to that of the DCOG ALL10 high-risk arm. Cumulative
incidence of relapse and non-response was estimated using a competing
risks model and compared using Gray's test. Event-free survival
probabilities were estimated using the actuarial Kaplan–Meier method
and compared using the log-rank test. Hazard ratios were calculated in
SPSS v21 using Cox’s proportional hazard model. Outcome analyses were
performed in R 3.2.1, using the packages cmprsk46 version 2.2-7, mstate
version 0.2.747 and survival version 2.38-3.48
RESULTS
Frequency and clonality of RAS pathway mutations in newly
diagnosed pediatric BCP-ALL
Targeted amplicon deep sequencing was used to identify RAS
pathway mutations in samples from 461 children with BCP-ALL at
initial diagnosis. Mutational hotspots in 13 key members of the
RAS pathway were analyzed with 49 amplicons. The median read
depth per amplicon was 1085 reads per sample (IQR: 527–2647)
(Supplementary Table S1 and Supplementary Figure S2).
Most recurrent lesions were activating mutations in NRAS
and KRAS (79%), followed by mutations in PTPN11 and FLT3
(9.3% and 10.1%, respectively; Figure 1a and Supplementary
Figure S3). Mutations in BRAF, NF1, CBL and other genes occurred
sporadically. Overall, variants in RAS pathway genes were
observed in 44.2% of pediatric BCP-ALL cases. Clonal mutations
(VAF⩾ 25%) were found in 24.1% of all patients (median: 40.5%
VAF; Supplementary Figure S4) and subclonal mutations
(VAFo25%) were exclusively found in 20.1% of patients (median:
4.3% VAF).
Most cases with RAS pathway mutations were high hyperdi-
ploid or those with rare or negative for BCR-ABL1, ETV6-RUNX1,
TCF3-PBX1, MLL-rearrangement and high hyperdiploidy (51–67
chromosomes), including non-BCR-ABL1-like ‘B-other’ and BCR-
ABL1-like cases (Figure 1b and Supplementary Table S3). Mutation
frequencies were high in BCR-ABL1-like (49.4%), B-other (41.8%),
high hyperdiploid (72.6%) and t(4;11)-rearranged (MLL-AF4, 73.3%)
cases, with clonal mutations observed in 31.6%, 25.4%, 41.9% and
20%, respectively (Figure 1b). Comparison of each subtype to the
remaining BCP-ALL cases showed signiﬁcantly more mutations in
cases with MLL-rearrangement and high hyperdiploid karyotype
(odds ratio 3.8 and 5.7, respectively), and signiﬁcantly less
mutations in cases with ETV6-RUNX1-, TCF3- and BCR-ABL1-
rearrangement (odds ratios o0.3; Supplementary Table S4).
Interestingly, within the BCR-ABL1-like group RAS pathway
mutations were mutually exclusive with ABL/JAK class tyrosine
kinase fusions, but not with high CRLF2 expression
(Supplementary Figure S5). ETV6-RUNX1-rearranged cases showed
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an intermediate frequency (26.6%, 10.5% clonal), and TCF3-PBX1-
or BCR-ABL1-rearranged cases had the lowest frequencies with 8%
(0% clonal) and 4% (4% clonal) of cases being affected,
respectively.
Frequent secondary aberrations in clonal RAS pathway
mutant cases were chromosome 21 aberrations, dic(9;20)
chromosomes, 9p-deletion, PAX5 ampliﬁcations and CDKN2A/B
deletions. Opposed to that, signiﬁcantly less BTG1 deletions
and ETV6 deletions were detected in cases with clonal RAS
pathway mutations. Cases with subclonal RAS pathway
mutations also more frequently carried chromosome 21
aberrations and additionally more often expressed high CRLF2
and harbored less mutations in IKZF1 and PAX5 (Supplementary
Table S5).
All except three NRAS mutations and three quarters of the KRAS
mutations affected the codons 12 and 13 (Supplementary
Figure S6).
Although clonal RAS pathway mutations were mutually
exclusive (Figure 1a), additional subclonal mutations were present
in 41% of cases with a clonal mutation and in 49% of cases with a
Figure 1. Frequency and distribution of RAS pathway mutations in pediatric BCP-ALL. (a) Overview of all clonal or subclonal mutations found
in pediatric BCP-ALL cases at initial diagnosis. Top bar represents the cytogenetic subtype. Black boxes represent clonal mutations (variant
allele frequency (VAF)⩾ 25%) and gray boxes represent subclonal mutations (VAF o25%). (b) Frequency of clonal and subclonal RAS pathway
mutations overall and within the cytogenetic subtypes. BA, BCR-ABL1-rearranged; BAL, BCR-ABL1-like; BO, B-other; ER, ETV6-RUNX1-rearranged;
HD, high hyperdiploid; MLL, t(4;11)-rearranged; TCF3, TCF3-PBX1-rearranged. (c) Co-occurrence of RAS pathway mutations: bar heights indicate
the frequency of mutated cases carrying the number of RAS pathway mutations indicated on the x-axis. Segmentation of each bar indicates
the distribution of mutated genes.
Table 1. Incidence of clonal RAS pathway mutations among BCP-ALL patients with clinical risk factors
Risk parameter Incidence of clonal mutations among Statistics (clonal vs wild type)
Risk parameter: Yes Risk parameter: No Fisher’s Odds ratiob 95% CI
Pa
Age ⩾ 10 22/75 (29%) 90/357 (25%) 0.88
Male 55/227 (24%) 57/205 (24%) 0.56
High WBC (450/nl) 34/99 (34%) 78/331 (24%) 0.24
Down syndrome 2/16 (13%) 105/305 (27%) 0.10 0.3 0.03–1.38
CNS+ 0/1 (0%) 24/248 (10%) 1
PPR 7/17 (41%) 51/181 (21%) 0.15 2.22 0.65–7.41
MRD high d33 ALL10 16/48 (33%) 35/147 (18%) 0.01 2.99 1.27–7.05
MRD high d79 ALL10 2/8 (25%) 47/171 (20%) 1
Abbreviations: CNS+, non-traumatic puncture and 45 WBC/μl CSF with identiﬁable leukemic cells; patients with a traumatic lumbar puncture were not
included; d33, at the end of induction therapy (day 33); d79, at the end of consolidation therapy (day 79); PPR, prednisone poor responder, that is, ⩾ 1000
leukemic blasts/μl in peripheral blood on day 8 of induction therapy; MRD high, minimal residual disease ⩾ 10−3; WBC, white blood cell count. aFisher’s exact
test P-values o0.05 are printed in bold font. bOdds ratios are only given if P-values in Fisher’s exact test were o0.2.
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subclonal mutation (46.2% of all mutated patients; Figure 1c).
Most of these additional RAS pathway mutations were present at a
VAF o10% (Supplementary Figure S4).
Clinical characteristics and outcome
Clinical characteristics were compared between BCP-ALL cases
with clonal RAS pathway mutations (n= 110, KRAS, NRAS, PTPN11
or FLT3) and wild-type cases (n= 235). Age, white blood cell count,
gender, Down syndrome, CNS status at diagnosis and prednisone
window response at day 8 of therapy did not differ signiﬁcantly
(Table 1). In DCOG ALL10 patients clonal mutations were enriched
among cases with high MRD levels (⩾10−3) after 4 weeks of
induction treatment (33% in of MRD-high vs 18% in MRD-low
cases, P= 0.01). This had an impact on mutation frequencies in the
actual treatment arms: 13.5% of cases in the standard-risk arm
carried a clonal RAS pathway mutation, compared with 21.9% in
medium risk and 40.9% in the high-risk treatment arm
(Supplementary Table S6, P= 0.02).
In contrast, subclonal mutations were not associated with poor
risk features. These mutations were signiﬁcantly more common
among younger children (P= 0.04), those with low white blood
cell counts (o50 cells/nl, P= 0.02), and those in the medium-risk
treatment arm (P= 0.01; Supplementary Table S7).
The prognostic value of RAS pathway mutations was analyzed
in 244 newly diagnosed BCP-ALL patients treated according to the
DCOG ALL10 protocol (for baseline characteristics and cohort
composition see Supplementary Table S8 and Supplementary
Figure S1). In the total cohort, clonal and subclonal RAS pathway
mutations did not associate with an inferior clinical outcome
(Table 2 and Figure 2a). In the DCOG ALL10 study, patients are
risk-stratiﬁed by MRD response on day 33 and day 79 into
standard-risk, medium-risk and high-risk treatment arms. In
standard- and high-risk-treated cases clonal RAS pathway muta-
tions were associated with a signiﬁcantly worse event-free survival
compared with wild-type cases, caused in part by a higher
incidence of relapse and non-response (Table 2 and Figure 2b, red
lines). Signiﬁcantly fewer relapses occurred in medium-risk-treated
patients harboring clonal mutations compared with wild-type
cases, which resulted in a trend for better event-free survival.
Subclonal mutations were not predictive for outcome (Figure 2b,
blue lines).
Univariate analysis of RAS pathway status in these three risk
arms revealed that clonal but not subclonal mutations in RAS
pathway genes were predictive for an unfavorable outcome in the
standard-risk-treated group (hazard ratio 4.6, P= 0.047), which
remained prognostic in a multivariate analysis including WBC and
age (hazard ratio 5.4, P= 0.032; Supplementary Table S9).
Univariate analysis of RAS pathway mutations in the medium-
risk and high-risk groups did not reveal statistical signiﬁcant
associations with event-free survival in this DCOG ALL10 study
cohort.
The impact of RAS pathway mutations on clinical outcome was
also evaluated in the COALL97/03 cohort (Supplementary
Figure S7). These patients had been stratiﬁed into treatment arms
according to white blood cell count, age, immunophenotype and
ex vivo drug response. Small group sizes are limiting this analysis
and differences were not statistically signiﬁcant, but the trends
support our results of the DCOG ALL10 study. In standard-risk-
treated cases, those with clonal but not subclonal mutations more
often suffered from a relapse than did non-mutated cases,
whereas this prognostic impact was absent in the medium-risk-
treated group (Supplementary Figure S7).
Ex vivo resistance to chemotherapeutic agents
Ex vivo cytotoxicity data of prednisolone, L-asparaginase, vincris-
tine, daunorubicin, 6-mercaptopurine and 6-thiopurine were
available for 211 cases. RAS pathway-mutated cells were median
threefold more resistant to prednisolone compared with wild-type
cases (Figure 3a; P= 0.024). Leukemic cells harboring clonal or
subclonal KRAS G13 mutations were most resistant to predniso-
lone: these cells were median 42000-fold more resistant
compared with wild-type cells (P= 0.001 and P= 0.006, respec-
tively; Supplementary Table S10, Figure 3a and Supplementary
Figure S8). Clonal NRAS G13 mutations showed a trend, but the
Table 2. Clinical outcome of patients with clonal or subclonal RAS pathway mutations
Mutation status n EFS CIR
5-year EFS in % (s.e.) Cox’s hazard ratioa Log-rank 5-year CIR in % (s.e.) Gray’s test
Pcl Pcl
ALL10b
Wild type 135 92 (2) 8 (2)
Mutated 109 86 (3) 11 (3)
ALL10b
Wild type 135 92 (2) 8 (2)
Subclonal 59 88 (4) 11 (4)
Clonal 50 84 (5) 10 (4)
SR
Wild type 49 96 (3) 4 (3)
Subclonal 15 93 (6) 7 (7)
Clonal 10 69 (15) 4.57 (CI: 1.02-20.5) 0.027 21 (14)
MR
Wild type 75 88 (4) 12 (4)
Subclonal 42 85 (6) 12 (5)
Clonal 31 97 (3) 0.058 0 0.01
HR
Wild type 11 100 0
Subclonal 2 N/Ac N/Ac
Clonal 9 56 (16.6) 0.015 33 (17) 0.044
Abbreviations: CIR, cumulative incidence of relapse and non-response; EFS, event-free survival; HR, high risk; MR, medium risk; n/a, not applicable; Pcl, P-value
for comparison clonal vs wild-type cases; SR, standard risk. Only P-values o0.1 are shown. aOnly shown if signiﬁcantly different, reference group: wild-
type cases. bAll tests stratiﬁed for risk arms of this protocol (SR, MR and HR). c5-year follow-up only reached by one patient. Values of Po 0.05 are printed in bold.
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Figure 2. Clinical outcome of patients carrying clonal or subclonal RAS pathway mutations. Event-free survival (left panel) and cumulative incidence
of relapse and non-response (CIR, right panel) (a) within the ALL10 cohort (n=244) and (b) divided by the three risk arms of ALL10. Abbreviations:
HR, high-risk group; MR, medium-risk group; Ptrend represents the P-value in a log-rank (EFS) or Gray-test (CIR) across all three groups, Pcl represents
the P-value in a log-rank or Gray-test comparing wild-type patients and those with a clonal RAS pathway mutation; SR, standard-risk group.
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difference was not signiﬁcant (P= 0.18). NRAS and KRAS G12
mutations did not signiﬁcantly affect resistance towards
prednisolone, although several cases were highly resistant.
Mutations in PTPN11 and FLT3 were not associated with cellular
prednisolone resistance (Supplementary Table S10 and
Supplementary Figure S8A).
Ex vivo cytotoxicity of the tubulin-inhibitor vincristine was also
reduced in RAS pathway-mutated cells (Figure 3b): Cases with a
clonal KRAS or PTPN11 mutations were signiﬁcantly more resistant
to vincristine compared with wild-type cases (15-fold, P= 0.005
and 5-fold, P= 0.041, respectively). A trend was observed for clonal
NRAS G13 mutations (3-fold, P= 0.074). No signiﬁcant difference
was observed for KRAS G12 mutations, and an inverse trend was
found in cases carrying an NRAS G12 mutation (5-fold decrease,
P= 0.057, see also Supplementary Figure S8B).
In K/NRAS G13-mutated cases the glycine (G) was replaced by
an aspartic acid (D) in 13 of 15 cases. In contrast, the type of amino
acid being substituted at the G12 position was more variable (see
also Supplementary Figure S6). As visualized in Supplementary
Figure S9 the substituting amino acid was not predictive for
ex vivo prednisolone or vincristine resistance.
In contrast, wild-type cases tended to be more resistant towards
L-asparaginase ex vivo than RAS pathway-mutated cases; however,
this trend was not signiﬁcant (Supplementary Table S10). No
consistent association of mutation status with ex vivo drug
response was observed for daunorubicin, 6-thioguanine and
6-mercaptopurine (Supplementary Figure S10).
RAS pathway mutations at relapse
RAS pathway mutations were detected in 13 out of 19 cases with
matched initial diagnosis and relapse samples (Figure 4). Ten
mutations were found at diagnosis, and 10 at relapse (53%). From
diagnosis onwards, the evolution of RAS pathway mutations
followed three distinct patterns: In three cases, a clonal RAS
pathway mutation was detected at initial diagnosis and at relapse
(‘Retained’). In seven cases, a subclonal mutation (four patients) or
no mutation (three patients) was observed at diagnosis, but at
relapse a RAS pathway mutation was detected with higher VAF
(‘Gained’). In six of these relapses the mutation was clonal,and in
one it was subclonal. One of these cases was remarkable in that
ﬁve different subclones were observed at diagnosis but only one
of these mutations (NRAS G12S) was found at relapse. Loss of one
and selection of a second clone was observed in two cases, where
they constituted the major clone in all subsequent relapses. In
three cases, the initially observed RAS pathway mutation was not
detected at relapse (‘Lost’). For all ‘lost’mutations VAF at initial
diagnosis was lower than 10%. Remarkably, in 9 out of 10 relapse
Figure 3. RAS pathway mutations and ex vivo cytotoxicity of chemotherapeutic agents. Ex vivo sensitivity of 211 primary patient samples
towards (a) prednisolone and (b) vincristine, distinguished by RAS mutation status. Only clonally mutated cases are considered. Only KRAS-
and NRAS-mutated groups are shown due to low recurrence of other mutations (see also Supplementary Data). Combined: All cases with a
clonal mutation in NRAS, KRAS, PTPN11, FLT3. Groups were compared by Mann–Whitney U-test, *Po0.05, **Po0.01. LC50-values were
evaluated by MTT assays as reported previously.
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cases a single, clonal mutation was observed (VAF of 27% or
higher).
MEK inhibitors as therapeutic option
The MEK inhibitor trametinib was cytotoxic to RAS mutant but not
to wild-type leukemic cells in a range of concentrations (Figure 5a
and Supplementary Figure S11A). This effect is also illustrated by
individual data points at a ﬁxed concentration of 0.14 μM
(Figures 5b, P= 0.001). High levels of MEK1/2 and ERK1/2
phosphorylation indicated an activated RAS pathway in mutant
but not in wild-type cells (Figure 5c). The cytotoxicity of increasing
trametinib concentrations corresponded with effective reduction
of ERK1/2 phosphorylation (Supplementary Figure S11B). In
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Figure 5. The MEK inhibitor trametinib effectively kills RAS mutant primary BCP-ALL cells. (a) Sensitivity towards the MEK inhibitor trametinib
in primary or xenograft-derived BCP-ALL cells. Mean and standard deviation are shown. (b) Relative cell survival at 0.14 μM trametinib split up
per case. Gray circles represent wild-type cases; red triangles represent RAS pathway mutant cases. Bars represent group mean. Groups were
compared by Mann–Whitney U-test, ***P= 0.001. (c) Western blot analysis of phospho-ERK (T202/T204) and phospho-MEK (S217/S221) in a
subset of samples tested in (a). †Sample isolated after thawing, cells previously tested positive. (d) Ex vivo response to trametinib (left panels)
and sensitization towards prednisolone (right panels) in one NRAS G12D-mutant and one RAS pathway wild-type case.
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addition, we found that intrinsic resistance to prednisolone could
be reversed by trametinib irrespective of RAS mutation status
(Figure 5d), which corroborates our previous ﬁndings.30
DISCUSSION
The RAS pathway is the most frequently mutated pathway in
cancer, and may serve as treatment target.7,8,49 Recent reports
suggest that RAS pathway mutations are recurrent in pediatric
BCP-ALL.20,27,30,31,50 However, frequency and prognostic value of
subclonal mutations at initial presentation were unknown. In this
study we addressed the clinical value of mutations in 13 key
members of the RAS pathway using deep targeted sequen-
cing, which allowed detection of subclones down to 1% VAF.
Our study cohort contained 461 newly diagnosed cases and
represents all subtypes and risk groups of BCP-ALL, with a
distribution comparable to the general pediatric BCP-ALL
population.
We identiﬁed clonal RAS pathway mutations (⩾25% VAF) in
24.1% and subclonal mutations (o25% VAF) in 20.1% of patients
at initial diagnosis. This total of 44.2% is considerably higher than
the 15% mutation frequency previously detected by Sanger
sequencing, and shows that RAS pathway activation cooperates
with several primary oncogenic lesions.20,31 The vast majority of
mutations (98%) occurred in NRAS, KRAS, FLT3 and PTPN11,
revealing a central role of these genes in pediatric BCP-ALL.
We observed high mutation frequencies among high hyperdi-
ploid, MLL-AF4-rearranged, BCR-ABL1-like and B-other cases,
moderate frequencies among ETV6-RUNX1 cases, and rarely
observed them in TCF3-PBX1 and BCR-ABL1-rearranged cases,
conﬁrming reports of smaller sample sets.23,27,32,51
The BCR-ABL1 fusion is known to require MAPK signaling, but
the low mutation frequency suggests that independent RAS
pathway activation is not required for this aggressive disease.52–56
BCR-ABL1-like cases, who bare strong similarities with BCR-ABL1-
positive leukemia, frequently carry RAS pathway mutations. These
were mutually exclusive with tyrosine kinase fusions, suggesting
divergent pathogenic mechanisms. Our data further show that
RAS pathway activating mutations play a role in about half of all
B-other patients. The largest group of RAS pathway-mutated cases
was observed within high hyperdiploid cases. Our extensive
screen extends the existing knowledge by revealing frequent
subclonal events.27,32,57,58 Our data advocate MEK inhibitors as a
treatment option in high hyperdiploid cases with poor therapy
response. We further identiﬁed several secondary aberrations that
co-occurred less or more frequently with RAS pathway mutations.
Interestingly, RAS pathway mutant cases infrequently carried BTG1
deletions, which have recently been linked to glucocorticoid
resistance and may represent a distinct resistance mechanism in
RAS pathway wild-type cases.59
In the largest data set analyzed so far (n= 211), we conﬁrmed
the association of RAS pathway mutations with prednisolone
resistance.30,60,61 Additionally, RAS pathway mutant cells were
ex vivo resistant to vincristine, but not to L-asparaginase,
daunorubicin and thiopurines. This suggests that patients with
RAS pathway mutations could proﬁt from intensiﬁcation of
these drugs.
Patients with high MRD levels (⩾10− 3 after induction or
consolidation) are at higher risk for relapse and treated more
intensely, also in DCOG ALL10.4,62 Patients with clonal RAS
pathway mutations treated in the DCOG standard-risk arm had
an unfavorable clinical outcome despite negative MRD levels.
Since the prognosis of clonally mutated patients is highly
favorable in the medium-risk group (5-year event-free survival
97%, cumulative incidence of relapse and non-response 0%;
Figure 2b), MRD-low risk patients with clonal RAS pathway
mutations may beneﬁt from medium-risk treatment, which
includes intensive PEG-asparaginase and dexamethasone/
vincristine pulses during maintenance therapy.4 This is further
supported by RAS-mutated patients being relatively sensitive to
asparaginase ex vivo. The prognosis of those 20.1% of patients
with subclonal mutations was similar to wild-type cases, and they
generally presented with good risk features. Therefore, subclonal
mutations in RAS pathway genes should not be used to assign
patients to a higher risk group or treatment with an MEK inhibitor.
Evaluation of 19 cases with matched diagnosis and relapse
material gave an important insight into the evolution of RAS
pathway mutations: (1) clonal mutations at diagnosis were
preserved at relapse, (2) subclonal mutations detected at initial
diagnosis were often found at relapse and (3) a single, clonal
mutation was found in 9 out of 10 relapses. These observations
conﬁrm that RAS pathway mutations are frequent at relapse in
pediatric BCP-ALL.28,29,63,64 The reduced mutational diversity at
relapse suggests outgrowth of a single clone with stronger
dependence on MAPK signaling, which may increase the chance
of success for RAS-targeted therapy.
NRAS and KRAS mutations increase the risk for therapy failure at
relapse, demanding alternative treatment options.27,28 These
patients may be eligible for MEK inhibitors such as trametinib.
Leukemic cells with RAS pathway mutations were sensitive to
trametinib, while wild-type cells were not. We further conﬁrm our
previous ﬁnding that MEK inhibition can synergize with
prednisolone.30 Interestingly, 9 of 11 RAS-mutated cases allocated
to the high-risk arm had a poor in vivo response to prednisone
after 1 week of therapy. This provides a rationale to combine MEK
inhibitors with glucocorticoids. Notably, within our data no
correlation was observed between the response to prednisolone
and the response to trametinib.
In conclusion, clonal mutations in NRAS, KRAS, PTPN11 and FLT3
are associated with therapy resistance. Given that clonal muta-
tions at initial diagnosis were retained at relapse and that
subclonal mutations often expanded at relapse, RAS pathway
mutations may serve as a biomarker to identify patients eligible
for MEK/ERK targeted therapy. The synergistic effect between MEK
inhibition and prednisolone may be of additional advantage.
While our results and supremacy of MEK inhibitors require
conﬁrmation in independent cohorts, our data suggest screening
(a) all cases that are eligible for treatment reduction based on
MRD and (b) patients for whom treatment intensiﬁcation is
advised and who may beneﬁt from adjuvant MEK inhibitor
treatment. Methodically, accurate detection of any clonal RAS
pathway mutation should be ensured, but detection of subclonal
mutations is not required.
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